SOPHiA GENETICS (SOPH) CMO sells 5,000 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu completed an open-market sale of 5,000 Ordinary Shares on 2026-07-13 at a weighted average price of $5.701 per share, with individual trade prices between $5.55 and $5.79, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Following the transaction, he directly holds 228,387 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($28,505)

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($29K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,000	$5.701	$29K

Holdings After Transaction: Ordinary Shares — 228,387 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.55 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $5.701 per share Sale price range: $5.55–$5.79 per share +1 more

4 metrics

Shares sold 5,000 shares Open-market sale on 2026-07-13 by Chief Medical Officer Philippe Menu

Weighted average sale price $5.701 per share Average price for the 5,000 Ordinary Shares sold on 2026-07-13

Sale price range $5.55–$5.79 per share Price range of multiple transactions comprising the reported sale

Shares held after transaction 228,387 shares Directly held Ordinary Shares by Philippe Menu after the sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported is a weighted average price for shares sold."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"Transaction code S reflects an open-market sale of Ordinary Shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"The security involved in the transaction is described as Ordinary Shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 04:03 PM Accepted by SEC EDGAR 07/14/2026 - 04:02 PM Learn about SEC filing dates

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Philippe Menu?

Chief Medical Officer Philippe Menu sold 5,000 SOPHiA GENETICS Ordinary Shares on 2026-07-13 in an open-market transaction. The sale was executed under a duly adopted Rule 10b5-1(c) trading plan and used a weighted average pricing across multiple trades.

At what price were SOPHiA GENETICS (SOPH) shares sold in Philippe Menu’s July 2026 trade?

The reported weighted average sale price was $5.701 per share for the 5,000 shares sold. Individual trades occurred at prices ranging from $5.55 to $5.79, with the insider offering to provide full breakdowns upon written request.

How many SOPHiA GENETICS (SOPH) shares does Philippe Menu hold after this sale?

After the transaction, Chief Medical Officer Philippe Menu directly holds 228,387 Ordinary Shares of SOPHiA GENETICS SA. This figure reflects his position immediately following the 5,000-share open-market sale reported for 2026-07-13.

Was the SOPHiA GENETICS (SOPH) insider sale executed under a Rule 10b5-1 trading plan?

Yes. The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans pre-schedule trades, meaning the timing of this 5,000-share sale was set in advance rather than decided opportunistically.

What type of security did SOPHiA GENETICS (SOPH) insider Philippe Menu sell and how is it held?

Philippe Menu sold Ordinary Shares of SOPHiA GENETICS SA in a non-derivative, open-market sale. The filing identifies his ownership of these securities as direct, and he retained 228,387 directly held Ordinary Shares after the transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/13/2026		S		5,000(1)	D	$5.701(2)	228,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.55 to $5.79, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)